New Data for XL880, XL647 and XL184 to Be Presented at AACR...(.m. PDT / 9:00-11:00 p.m. EDT. During th...),Health

Date:10/8/2007

.m. PDT / 9:00-11:00 p.m. EDT. During the briefing, Exelixis management will review data for XL647, XL880 and XL184, in addition to other Exelixis compounds. This webcast may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com. An archive of the webcast will be available until 8:59 p.m. PST/11:59 p.m. EST on November 24, 2007. Access numbers for the replay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international). The replay passcode is 86296035.

The full list of abstracts to be presented at the meeting follows:

Phase 2 Clinical Abstracts

-- A Phase 2 study of the dual MET/VEGFR2 inhibitor XL880 in patients

(pts) with papillary renal carcinoma (PRC) (Abstract #B249)

-- A Phase II study of XL647 in Patients with Non-Small Cell Lung Cancer

(NSCLC) Enriched for Presence of EGFR Mutations (Abstract #B124)

Phase 1 Clinical Abstracts

-- A phase 1 dose-escalation study of the safety and pharmacokinetics (PK)

of XL184, a VEGFR and MET kinase inhibitor, administered orally to

patients (pts) with advanced malignancies (Abstract #A152)

-- A phase I dose-escalation study of the safety, pharmacokinetics, and

pharmacodynamics of XL820 administered orally daily (QD) or twice daily

(BID) to patients (pts) with solid malignancies (Abstract #B69)

-- Targeting aberrant PI3K pathway signaling with XL147, a potent,

selective and orally bioavailable PI3K inhibitor (Abstract #C205)

-- Biomarker development for XL765, a potent and selective oral dual

inhibitor of PI3K and mTOR currently being administered to patients in

a Phase I clinical trial (Abstract #B265)

-- A phase I dose-escalation and pharmacokinetic (PK) study of XL647, a

novel spectrum selective kinase inhibitor, administered orally daily to

patients with adv
'/>"/>

SOURCE Exelixis, Inc. Copyright©2007 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes